The Baculoviral IAP Repeat Containing Protein 5 pipeline drugs market research report outlays comprehensive information on the Baculoviral IAP Repeat Containing Protein 5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Baculoviral IAP Repeat Containing Protein 5 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Immunology which include the indications Glioblastoma Multiforme (GBM), Ovarian Cancer, Autoimmune Disorders, and Myasthenia Gravis. It also reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 targeted therapeutics development with respective active and dormant or discontinued products.
The Baculoviral IAP Repeat Containing Protein 5 pipeline targets constitutes close to 31 molecules. Out of which, approximately 24 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 9, 3, 3, 4, and 4 respectively. Similarly, the universities portfolio in Phase III, Phase I, Phase 0, and Preclinical comprises 1, 1, 1, and 4 molecule.
Baculoviral IAP Repeat Containing Protein 5 overview
Baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 also known as Survivin is a protein encoded by the BIRC5 gene. It has dual roles in promoting cell proliferation and preventing apoptosis. It acts as an important regulator of the localization of this complex directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. It counteracts a default induction of apoptosis in G2/M phase. It plays a role in neoplasia.
For a complete picture of Baculoviral IAP Repeat Containing Protein 5’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
